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Abstract: An imbalance of TNF signalling in the inflammatory milieu generated by meningeal
immune cell infiltrates in the subarachnoid space in multiple sclerosis (MS), and its animal model
may lead to increased cortical pathology. In order to explore whether this feature may be present
from the early stages of MS and may be associated with the clinical outcome, the protein levels of
TNF, sTNF-R1 and sTNF-R2 were assayed in CSF collected from 122 treatment-naïve MS patients
and 36 subjects with other neurological conditions at diagnosis. Potential correlations with other
CSF cytokines/chemokines and with clinical and imaging parameters at diagnosis (T0) and after
2 years of follow-up (T24) were evaluated. Significantly increased levels of TNF (fold change: 7.739;
p < 0.001), sTNF-R1 (fold change: 1.693; p < 0.001) and sTNF-R2 (fold change: 2.189; p < 0.001) were
detected in CSF of MS patients compared to the control group at T0. Increased TNF levels in CSF were
significantly (p < 0.01) associated with increased EDSS change (r = 0.43), relapses (r = 0.48) and the
appearance of white matter lesions (r = 0.49). CSF levels of TNFR1 were associated with cortical lesion
volume (r = 0.41) at T0, as well as with new cortical lesions (r = 0.56), whilst no correlation could be
found between TNFR2 levels in CSF and clinical or MRI features. Combined correlation and pathway
analysis (ingenuity) of the CSF protein pattern associated with TNF expression (encompassing
elevated levels of BAFF, IFN-γ, IL-1β, IL-10, IL-8, IL-16, CCL21, haptoglobin and fibrinogen) showed
a particular relationship to the interaction between innate and adaptive immune response. The
CSF sTNF-R1-associated pattern (encompassing high levels of CXCL13, TWEAK, LIGHT, IL-35,
osteopontin, pentraxin-3, sCD163 and chitinase-3-L1) was mainly related to altered T cell and B cell
signalling. Finally, the CSF TNFR2-associated pattern (encompassing high CSF levels of IFN-β, IFN-
λ2, sIL-6Rα) was linked to Th cell differentiation and regulatory cytokine signalling. In conclusion,
dysregulation of TNF and TNF-R1/2 pathways associates with specific clinical/MRI profiles and
can be identified at a very early stage in MS patients, at the time of diagnosis, contributing to the
prediction of the disease outcome.
Keywords: multiple sclerosis; TNF; cerebrospinal fluid; pathway analysis; inflammation
1. Introduction
TNF is one of the main inflammatory mediators involved in several pathological
conditions, including chronic inflammatory diseases such as multiple sclerosis (MS). TNF
Cells 2021, 10, 1712. https://doi.org/10.3390/cells10071712 https://www.mdpi.com/journal/cells
Cells 2021, 10, 1712 2 of 16
can be produced by several cell types, including immune cells (macrophages and T cells)
as well as central nervous system (CNS) cells (astrocytes and microglia). It plays a pivotal
role in many aspects of immune system development, immune response regulation and
T cell-mediated tissue injury [1], and may have both pro-inflammatory and immune-
regulatory properties, influencing the generation of the T cell repertoire, antigen-presenting
cell function and apoptosis of potentially autoreactive T cells [2]. These two different effects
are related to the activation of different inflammatory signalling pathways after binding
to the two different receptors: TNF-R1 and TNF-R2. TNFRs are membrane receptors that
can also be converted into soluble forms (sTNF-R1 and sTNF-R2) through the activity of
TACE enzymes. Both soluble receptors can interact with either sTNF or mTNF, the two
conformations of TNF. By binding preferably to TNF-R1, soluble TNF (sTNF) can mediate
apoptosis, necroptosis or pro-inflammatory signalling, while membrane TNF (mTNF)
can bind to both TNF-R1 and TNF-R2 to activate pathways involved in the resolution
of inflammation and tissue regeneration [3]. Under inflammatory conditions, TNF-R1
expression can be induced in several cell types and activated by both mTNF and sTNF,
while TNF-R2 is restricted to endothelial cells, various immune cells and certain CNS cells
and can be effectively stimulated by mTNF [4,5].
TNF has been detected both in the cerebrospinal fluid (CSF) of MS patients in corre-
lation with disease activity [6] and in MS white matter plaques, where it is suggested to
enhance inflammation and oligodendrocyte cell death [7].
We have recently shown that the balance of the TNF signalling in post-mortem MS
subpial cortical grey matter (GM) strongly correlates with the degree of meningeal inflam-
mation and is crucial in the evolution of the neurodegenerative pathology [8]. These data
were further validated by recent experimental models showing that persistent intrathecal
expression of TNF, in the presence of IFNγ, is a potent inducer of meningeal inflammation
and can lead to necroptotic neuronal death and subpial demyelination, and thus may
contribute to more severe clinical progression in MS [9,10].
Increased levels of TNF in the CSF of MS patients could be due to the pro-inflammatory
activity of resident activated glial cells, as well as the compartmentalised immune activity
within perivascular and meningeal infiltrates. In particular, we have previously demon-
strated in post-mortem MS cases with more extensive cortical pathology and more rapid
and severe disease progression that inflammatory cells infiltrating the leptomeninges may
represent a key source of TNF that is released in the CSF and may then mediate tissue
injury in the underlying cortical and deep grey matter [6,11]). In addition, a high level of
CSF TNF at the time of diagnosis was found to be associated with increased risk of Gad+
WML, new WML, the number of relapses and worsening EDSS after 4 years [12].
Here we aimed to perform a comprehensive evaluation of the clinical and MRI correlates
of the CSF presence of TNF and its soluble receptors, TNF-R1 and TNF-R2, in treatment-naïve
MS patients and the potential association with other inflammatory mediators.
2. Materials and Methods
2.1. MS Patient Cohorts
One hundred and twenty-two consecutive treatment naïve relapsing-remitting MS
patients arriving at the MS Centre of Verona University Hospital (Italy) were enrolled
at diagnosis between September 2014 and February 2015. All the MS patients had a
diagnosis of MS [13] (Polman 2011) and underwent neurological evaluation, 3T-MRI and
CSF examination at the time of diagnosis (T0). Each patient was then followed yearly
from a clinical and imaging point of view for 2 years (T24). The local Ethics Committee
approved the study. Informed consent was obtained from the patients (Protocol number
66418, 25 November 2019). Biological material was obtained from voluntary donors in
compliance with the Legislative Decree 196/2003 “Personal Data Protection Code”. Clinical
and demographic details of the examined MS population are reported in Table 1.
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Table 1. Demographic, clinical and MRI details of the MS examined population.
Mean Std. Deviation
Age at onset 35.36 12.24
Age at LP 37.78 12.71
EDSS T0 1.83 1.06
T2 WM lesions 8.29 3.76
T2WM lesions volume 835.10 502.70
Gad + lesions T0 0.13 0.48
Spinal cord lesions T0 0.51 0.96
CLs volume (cm3) T0 215.60 297.80
CLs number T0 7.72 5.90
EDSS change a T12 0.22 0.38
Relapse T0-T12 0.26 0.48
New T2 WM lesions T12 0.79 1.36
New Gad+ lesions T12 0.29 0.61
New spinal cord lesions T12 0.14 0.38
New CLs T12 0.88 1.48
EDSS change T12-T24 0.27 0.45
Relapse T12-T24 0.20 0.43
New T2 WM lesions T12-T24 0.70 1.12
NewGad+ lesions T12-T24 0.18 0.44
New spinal cord lesions T12-T24 0.14 0.34
New CLs T12-T24 0.82 1.31
Relapse T0-T24 0.44 0.76
EDSS change T0-T24 0.45 0.70
New T2 WM lesionsT0-T24 1.69 2.37
New Gad+ lesions T0-T24 0.46 0.85
Abbreviations: EDSS: expanded disability status scale; CL: cortical lesion; T2WMLV: T2 white matter lesion volume.
2.2. Control Population
Thirty-six age- and sex-matched patients affected by other neurological diseases, who
underwent neurological evaluation and CSF examination at the time of the diagnosis,
were included in the study. This group included 21 individuals with non-inflammatory
neurological diseases (NIND) (1 idiopathic tremor, 2 migraine, 2 amyloid angiopathy,
2 fibromyalgia, 4 ischemic stroke, 1 spondylotic myelopathy, 2 amyotrophic lateral sclerosis,
1 olivopontocerebellar atrophy, 1 idiopathic spastic paraparesis, 1 idiopathic ataxia, 1 my-
opathy, 1 endocranial hypertension, 2 peripheral neuropathy), and 15 subjects with other
inflammatory neurological diseases (OIND) (1 infective myelopathy, 2 CNS lymphoma,
2 intracranial abscess, 1 peripheral neuropathy, 2 Behcet’s disease, 3 neuromyelitis optica
spectrum disorder, 3 autoimmune encephalitis, 1 aseptic meningitis). The Ethics Committee
of the University of Verona approved the study, and informed consent was obtained from
all participants.
2.3. MRI Acquisition Protocol and Analysis
For each patient, an MRI was performed at least 2 months after the last relapse. MRI
sequences were acquired using a Philips Achieva 3T MR Scanner. The following image sets
were acquired: 3D T1 weighted; 3D double-inversion recovery (DIR); 3D Fluid Attenuated
Inversion Recovery (FLAIR); 3D Echo Planar Susceptibility Weighted Imaging (EPI-SWI).
Optimised parameters for each sequence were set as previously published [14] (Calabrese
and Castellaro, 2017).
2.3.1. WM and CL Lesion Detection and Lesion Load Assessment
White matter lesions were assessed by a consensus of experienced observers. Attention
was paid to manually check the WM lesion map to identify and segment WM lesions, thus
obtaining a T2-hyperintense WM lesion volume (T2WMLV). A similar consensus procedure
was followed for the detection of CLs on DIR images, following recommendations for
scoring of CLs in patients with MS [15]. Moreover, CLs were sub-divided into leukocortical
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and intracortical based on visual assessment and the cortical lesion volume was obtained
as previously described [16].
2.3.2. Cortical Thickness Evaluation and T1 Parcellation
The estimation of the cortical thickness was performed using the 3D T1 sequence and
the automated, volume-based advanced normalisation tools (ANTs) and, in particular,
the ANTs cortical thickness pipeline. The mean cortical thickness in the whole GM was
calculated from the segmentation obtained with the cortical thickness pipeline. The segmen-
tation of T2 hyperintensity was used as a mask for the lesion filling of 3D T1 images. The
lesion filling was performed with the lesion filling routine included in the lesion segmenta-
tion tool [17]. The multi-atlas label fusion (MALF) technique implemented in ANTs [18]
was used to parcellate the sub-cortical GM (Thalamus, Putamen, Caudate and Pallidum).
The joint label fusion technique was then used to produce the final parcellation labelling.
2.4. Immunoassay CSF Protein Analysis
CSF samples were obtained at least 2 months after the last relapse and within one
week of the MRI (ethical approval n◦ 35315), according to consensus guidelines for CSF
and blood biobanking [19]. After centrifugation, the supernatant and the cell pellet were
stored separately at −80 ◦C until use. The IgG index and presence/absence of oligoclonal
bands (OCB) for each MS patient are reported in Table 1. The CSF analysis was optimised
and performed by two independent investigators (R.M. and S.R.), blinded with respect to
the clinical and MRI features. The levels of 69 inflammatory mediators (Supplementary
Table S1) were assessed using a combination of immune-assay multiplex techniques based
on the Luminex technology (40- and 37-Plex, Bio-Plex X200 System equipped with a mag-
netic workstation, BioRad, Hercules, CA, USA) as previously optimised [6] (Magliozzi et al.,
Ann Neur 2018). All samples were run in duplicate, and a number of the molecules were
analysed using different immune-assay platforms in order to verify the reproducibility and
consistency of the results. The CSF level of each protein detected during the analysis was
normalised to the protein concentration of each CSF sample as determined by the Bradford
procedure (Supplementary Table S1). When comparing the two groups of 21 NIND and
15 OIND controls, no differences were found in the presence and levels of the examined
molecules; therefore, the two groups were included as a single control group (Supplemen-
tary Table S1). The levels of neurofilament light chain (NF-L) were measured using the
human NF-light enzyme-linked immunosorbent assays (ELISA) kit (MyBioSource, San
Diego, CA, USA) and ELISA kit (#MBS135523, MyBiosource) for fibrinogen total anti-
gen, using VICTORTM X3 2030 Multilabel Plate Reader (Perkin Elmer, Walluf, Germany)
according to the procedures previously optimised [20].
2.5. Bioinformatic Investigation and Pathway Analysis
The CSF molecular profiles were scrutinised with ingenuity pathway analysis (IPA,
Qiagen, December 2020 Winter Release), which encompassed a manually curated knowl-
edge database of the relationship among molecules, signalling pathways and functional
annotations, based on the literature evidence. A core (functional) analysis was performed
on the clusters of molecules associated with TNF, sTNF-R1 and sTNF-R2, as well as on
the CSF profile of MS-High patients (as compared to MS-Low patients). IPA canonical
pathways (CPs) related to cellular immune response, humoral immune response, cytokine
signalling and nervous system signalling, as well as disease and functions categories,
were interrogated to determine the most relevant functional signatures and to produce
heatmaps and networks. Fisher’s exact test followed by Benjamini and Hochberg (B-H)
multiple testing correction was used to calculate whether the likelihood of the correlation
between molecules of the CSF profile and a specific annotation (either canonical pathway
or disease biofunction) was due to random chance. IPA z-score was also utilised to estimate
the activation state of a given functional annotation (positive z-score predicts an activa-
tion; negative z-score predicts an inhibition) [21]. Thresholds were set to p-value < 0.05
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and |z-score| > 0.5. In some cases, p-value was reported as the −log10; in this case, a
p-value < 0.05 corresponds to −log10(p-value) > 1.3.
2.6. Statistics
Non-parametric Mann–Whitney U tests were used to test differences in MRI, EDSS
and proteomic data between MS and control groups, as well as between MS-Low and
MS-High groups. Spearman correlation coefficients were calculated to analyse the strength
of correlation between clinical, MRI and CSF proteomic data, while Pearson correlation
was used to analyse CSF inter-molecular correlations. A false discovery rate (FDR) with a
significance level of 0.05 was adopted to correct for the multiple testing problem. Statis-
tical analysis was performed by using GraphPad PRISM-GraphPad Software, version 7
(GraphPad Software 2365 Northside Dr. Suite 560 San Diego, CA 92108, USA).
3. Results
3.1. Differential TNF/TNFRs Protein Expression at Time of Diagnosis
Increased levels of TNF (fold change: 7.739; p < 0.001), sTNF-R1 (fold change: 1.693;
p < 0.001) and sTNF-R2 (fold change: 2.189; p < 0.001) were detected in CSF of MS patients
compared to the control group at T0 (Figure 1). The increased TNF levels were associated
(p < 0.01) with increased EDSS change (r = 0.43), relapse rate (r = 0.48) and new white matter
lesions (r = 0.49) at T24. Elevated CSF levels of TNF-R1 were associated with higher cortical le-
sion volumes (r = 0.41) at T0, as well as with new cortical lesions (r = 0.56), whilst no correlation
could be found between TNF-R2 levels in CSF and clinical or MRI features (Figure 2a).
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Figure 1. Significant increased levels of TNF (*** p < 0.001), sTNFR1 (** p < 0.01) and sTNFR2 (*** p < 0.001) were detected in
the CSF of MS patients compared to the control group at time of diagnosis.
3.2. A Specific Pattern Related to Chronic Inflammation, Acute Phase Response, Dendritic Cells
and Neuroinflammation Is Associated with CSF Over-Expression of TNF and sTNFRs
By examining the inflammatory pattern associated with TNF/TNFRs CSF expres-
sion, increased levels of TNF were found to be significantly (p < 0.05) associated with
elevated levels of BAFF, IFN-γ, IL-1β, IL-10, IL-8, IL-16, CCL21, haptoglobin and fibrino-
gen (Figure 2b). Increased levels of TNF-R1 were significantly (p < 0.05) associated with
high levels of CXCL13, TWEAK, LIGHT, IL-35, osteopontin, pentraxin-3, sCD163 and
chitinase-3-L1 (Figure 2b). Finally, increased levels of TNFR2 were significantly (p < 0.05)
associated with high CSF levels of IFN-β, IFN-λ2 and sIL-6Rα (Figure 2b).
By performing pathway analysis of the CSF inflammatory patterns associated with
TNF or TNF-R1/2 expression, we found that the TNF-associated profile encompassed the
highest number of canonical pathways (n = 66) compared to the sTNF-R1 and sTNF-R2
patterns (n = 35 and n = 38, respectively; Figure 3a,b). Twenty-nine pathways were shared
among the three patterns, but the TNF-associated profile showed lower p-values in general
(i.e., higher −log10(p-value)) compared to the other two profiles, which were fairly similar
(Figure 3a). Communication between innate and adaptive immune cells, systemic lupus
erythematosus in B cell signalling pathway and altered T cell and B cell signalling in
rheumatoid arthritis were more significantly represented in the TNF profile compared
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to sTNF-R1 and sTNF-R2 (darker purple square in Figure 3a). HMGB1 signalling and
IL-17 signalling were shared with a similar p-value between TNF and sTNF-R1 profiles.
Other pathways related to TREM-1 signalling, B cell functions and IL-10 were significantly
represented in the TNF profile only (Figure 3b). The sTNF-R2 profile was mainly associated
with the role of cytokines in mediating communication between immune cells and T
helper cell differentiation, whereas other associated pathways showed less significant p-
values compared to the other two profiles. Finally, neuroinflammation signalling pathway,
dendritic cell maturation, acute phase response signalling and IL-6 signalling were shared
with similar p-values between the TNF and TNF-R1/2 patterns.
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cancer immunotherapy pathway) were shared among the three molecular patterns without remark-
able difference in terms of p-value. (b) Heatmap of CPs associated with at least one or two molecular
profiles indicated that TNF profile was characterised by the higher number of CPs when compared
to the other two molecular patterns. Among them, CPs related to TREM-1 signalling, B cells develop-
ment and IL-10 signalling were significantly annotated in the TNF profile only. For a comprehensive
list of molecules enclosed in each CPs see Supplementary Table S2.
3.3. Highest CSF Levels of TNF, sTNFR1 and sTNFR2 Were Present in MS Patients with
Increased Cortical Lesion Loads at the Time of Diagnosis
When we stratified MS patients according to the cortical lesion load, we found sig-
nificantly higher levels of TNF (p < 0.001), sTNF-R1 (p < 0.001) and sTNF-R2 (p < 0.01) in
MS-High patients (with high cortical lesion loads) with respect to MS-Low ones (with low
cortical lesion loads) (Figure 4). By analysing the CSF molecular profile associated with
the TNF/TNFRs differential expression in more detail, in the MS-High compared to the
MS-Low patients, 16 molecules were found to be differentially expressed in MS-High pa-
tients together with TNF and its TNFRs, including 14 up-regulated and 2 down-regulated
(Table 2).
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Figure 4. CSF levels of T F and sTNFRs in MS patients stratified according to the high (MS-High) or low (MS-Low) cortical
lesion load. Significa t increased levels of TNF (*** p < 0.001), sTNFR1 (** p < 0.01) and sTNFR2 (** p < 0.01) were detected
in CSF of MS-High compared to MS-Low patients at time of diagnosis.
Table 2. CSF inflammatory pattern associated with differential cortical lesion load.
Molecule MS-High MS-Low Fold Change
Mean StDev Mean StDev
T F-α *** 57.72 25.37 23.21 20.74 2.49
sTNF-R1 ** 6367.02 545.69 3465.76 1698.50 1.84
sTNF-R2 ** 1601.67 357.31 866.46 652.85 1.85
BAFF/ TNFSF13B ** 10,926.91 760.80 9049.70 6004.98 1.21
LIGHT/ TNFSF14 ** 663.90 105.88 156.56 256.93 4.24
IFN-γ ** 24.77 9.33 9.85 14.12 2.51
BCA-1/ CXCL13 *** 27.77 3.81 3.17 4.87 8.75
IL-10 ** 22.19 3.22 18.04 17.12 1.23
IL-22 * 52.64 26.72 33.62 36.19 1.57
IL-27(p28) * 271.39 51.76 139.56 171.48 1.94
Osteopontin/SPP1 ** 108,631.45 10,203.80 70,400.60 81,511.52 1.54
Pentraxin-3 * 529.91 72.04 282.65 414.24 1.87
sCD163 ** 55,404. 0 2111.60 44,373.96 35,703. 3 1.24
Chitinase 3-like 1 ** 52,758.42 4285.75 37,362.73 30,994.71 1.41
IgM * 707.97 61.54 346.19 338.14 2.05
Fibrinogen * 1483.38 184.83 941.78 6.64 1.58
NF-L * 2.82 0.68 1.62 0.95 1.74
IL-28A/IFN-λ2 * 243.89 67.45 350.47 91.71 0.57
IL-12(p70) * 9.00 3.87 13.81 2.53 0.62
* p < 0.05; ** p < 0.01; *** p < 0.001.
Cells 2021, 10, 1712 9 of 16
Following IPA core analysis of this CSF molecular profile, high-ranked pathways were
found to be related to altered T and B cell processes and to innate and adaptive immunity,
including: Altered T cell and B cell signalling in rheumatoid arthritis; role of cytokines in
mediating communication between immune cells; T helper cell differentiation; and commu-
nication between innate and adaptive immune cells (−log10(p-value) = 10.60, 7.64, 7.37 and
6.91, respectively; Figure 5). Interestingly, systemic lupus erythematosus in the B cell sig-
nalling pathway was predicted to be activated (−log(p-value) = 6.46, z-score = 2.00). Other
highly significant pathways with a positive z-score were related to dendritic cell function and
neuroinflammation, namely dendritic cell maturation (−log(p-value) = 4.37, z-score = 1.00)
and neuroinflammation signalling pathway (−log(p-value) = 3.71, z-score = 2.00).
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Figure 5. Most significant IPA canonical pathways recognised in the molecular profile of MS-High
patients as compared to MS-Low patients. HMGB1 signalling and systemic lupus erythematosus
in B cell signalling pathway exhibited a positive z-score, predicting an activation state; other CPs
related to T and B cells (altered T cell and B cell signalling in rheumatoid arthritis, role of cytokines
in mediating communication between immune cells, T helper cell differentiation and communication
between innate and adaptive immune cells) were significantly annotated, without an activation score.
Furthermore, other CPs with a significant z-score were PD-1 PD1-L cancer immunotherapy pathway,
IL-17 signalling and neuroinflammation signalling pathway. For the complete list of CPs of MS-High
profile see Supplementary Table S3.
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3.4. CSF Expression of TNF, sTNFR1 and sTNFR2 May Represent Surrogate Markers of
Meningeal Inflammation
According to the IPA Disease and Functions analysis, the most significant categories
associated with the CSF profile of MS-High patients were related to inflammatory disor-
ders as well as to immune cell processes (bars in Figure 6a). Inflammatory response and
lymphoid tissue structure and development (−log(p-value) = 11.51 and 12.77, respectively)
were further analysed to unravel functional annotations showing a meaningful z-score.
The inflammatory response encompassed many predicted activated functions related to
the adaptive immune response (z-score = 2.21), as well as to dendritic cells (quantity of
dendritic cells z-score = 1.97), antigen-presenting cells (accumulation and activation of
antigen-presenting cells, z-score = 1.17 and 1.37) and B cells (activation of B lymphocytes
z-score = 1.54; Figure 6b). Intriguingly, inflammation of meninges was also predicted
to be activated in the MS-High profile (z-score = 1.11). Processes related to T lympho-
cytes were also present, including cytotoxic T lymphocyte response, which was predicted
to be inhibited (z-score = −1.372). The investigation of lymphoid tissue structure and
development category confirmed the involvement of B lymphocytes and dendritic cells
(proliferation, maturation and differentiation of B lymphocytes, z-score = 2.17, 1.98 and
1.96; maturation of dendritic cells, z-score = 1.28; Figure 6c). In addition, formation of
germinal centre was also significantly annotated and activated (z-score = 1.07). Some of the
functional annotations related to T lymphocytes showed opposing trends, as indicated by
both positive and negative z-scores (differentiation of naive T lymphocytes, z-score = 1.96;
quantity of regulatory T lymphocytes, z-score = 0.95; quantity of CD8+ T lymphocyte,
z-score = −0.98; quantity of T lymphocytes, z-score = −1.01). Networks of molecules in
the CSF profile of MS-High patients, which contributed to the z-score of some functional
annotations described above, are depicted in Figure 6d,e.
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significant B-H corrected p-values related to inflammation (infl mmatory response and disease,
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immune cell trafficking). See Suppl mentary Table S4 for the complete analysis of disease and func-
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annotations marked by red asterisk were further utilised to generate networks in panel (d,e). For
the complete list of the annotations enclosed in the two categories see Supplementary Tables S5
and S6. (d,e) Networks from selected annotations of inflammatory response (d) and lymphoid tissue
structures and development categories (e) pinpointed an involvement of adaptive immunity and B
cell response; conversely, annotations related to T cell response were associated with negative z-score,
predicting an inhibition state. Notably, inflammation of meninges was also found to be activated:
this prediction was supported by the increased expression of IFN-γ, TNFRS1B/TNF-R2 and TNF
(orange arrows), whereas TNFRS1A/TNF-R1 showed an inconsistent relationship (yellow arrow).
Furthermore, the activation state of formation of germinal centre was supported by the increased
expression of CXCL13, BAFF/TNFRSF13B and TNF (orange arrows), whereas the upregulation
of IL-27 was inconsistent with the prediction (yellow arrow); the effect of the relationship with
TNFRSF1A/TNF-R1 could not be predicted (grey arrow).
4. Discussion
Sustained TNF expression has a key role in the target organ pathology of several
chronic inflammatory diseases, such as multiple sclerosis. Here, we have demonstrated
that the overexpression of TNF and sTNFRs in the CSF of early diagnosed MS patients is
associated with a particular clinical/MRI profile and a concomitant specific CSF molecular
pattern. In particular, CSF levels of TNF and sTNF-R1, but not of sTNF-R2, at the time
of diagnosis correlated with evidence of disease activity after 2 years, as shown by the
number of relapses, new white and grey matter lesions and increased EDSS score. These
data support the experimental evidence that TNF mediates pro-inflammatory events,
in particular by activating TNF-R1 signalling and suggest that selective TNF/TNF-R1
inhibition rather than complete TNF blockade may reduce the pro-inflammatory effects of
TNF, thus preserving relevant neuroprotective and repair signals that occur via TNF-R2
signalling [22–25].
The correlation found between signs of clinical disease activity in MS patients at the
time of diagnosis, such as increased EDSS change, an elevated number of relapses and
new white matter and cortical lesions, and CSF levels of TNF and TNF-R1, demonstrates
that the CSF molecular signatures of the disease phenotype can already be identified at
the earliest stages of MS [12,26,27]. In particular, CSF TNF may represent one of the best
biomarkers of cortical pathology, at least in a subgroup of MS patients [6,28].
In addition, pathway analysis suggested that an imbalance in TNF/TNFRs expression
in the CSF may represent a surrogate marker of meningeal inflammation and, possibly,
of germinal centre formation. This result strongly supports our previous finding that the
change in the balance of TNF-R1 versus TNF-R2 mediated signalling in post-mortem MS
cases at the gene expression level is related to the presence of meningeal inflammation
organised in tertiary lymphoid-like structures, to diffuse GM pathology and to more
rapid and severe disease progression [8]. Therefore, it can be confirmed that meningeal
inflammation almost certainly plays a crucial role in MS pathology since the initial stages
of the disease. CSF inflammatory biomarkers, as well as imaging methodologies detecting
GM lesions, may represent the only currently available tools to identify MS patients that
already have a meningeal inflammation-driven phenotype at the time of diagnosis. In
particular, CSF levels of TNF and TNFRs may represent one of the best correlations of
intrathecal inflammation that can be examined at the time of diagnosis and possibly during
the disease follow-up.
The advanced pathway analysis revealed that different cellular and humoral response
pathways were strongly associated with the TNF profile, with a partial overlap with sTNF-
R1 and sTNF-R2, particularly in a subgroup of MS patients characterised by the highest
level of cortical demyelination and CSF inflammation, strongly supporting a strict correla-
tion between TNF and B cell activity in MS. However, while TNF is well known to play
a key role in developmental lymphoid organogenesis and physiological B cell functions,
it remains less clear whether an aberrant activation of some B cell functions or defects in
regulatory B cell activity may be associated with the deregulation of TNF signalling path-
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ways. By releasing IL-10, TGF-β, IgM and IL-35, as well as by expressing FasL, and other
costimulatory factors, such as CD40, CD80/86 and PDL1, B-cells have been demonstrated
to have a key role in regulating TNF expression/production by CD4 T cells and mono-
cytes/macrophages [29]. At the same time, the strong correlation between TNF pathways
and B cell activity in the CSF highlights the key role in chronic inflammatory diseases, such
as MS, of the interaction between innate immune cell activity (microglia/macrophages)
and adaptive B cell responses. Several molecules produced by B cells, such as IL-10 and
IL-35, as well as an increased function of B cells as antigen-presenting cells (APCs), were
associated with higher activation of macrophages and pro-inflammatory T cells in MS and
other autoimmune diseases [30]. Therefore, it is important to better clarify the MS-specific
TNF-mediated molecular mechanisms regulating B cell immunity in MS.
TNF has been proposed as a principal pro-inflammatory mediator in MS pathogenesis
and its levels associated with disease progression, but, surprisingly, the systemic blockade
of TNF in some MS patients led to immune activation and increased disease activity, as
demonstrated by two clinical trials involving the use of antibody-based TNF antagonists
in patients with demyelinating disease [31,32]. The first tested infliximab, a humanised
mouse anti-TNF monoclonal antibody on two patients with RRMS, which provoked an
increase in disease activity at MRI. Lenercept, a recombinant soluble TNF-R1 fusion protein,
was tested in the second trial on 168 patients and caused a deterioration of the clinical
course in some patients compared to controls. These results were likely to have been due
to the non-selective TNF inhibition, as both effectively block sTNF and mTNF, which can
have opposing effects. The use of selective inhibition of TNF-R2 with a soluble TNF-R2
fusion protein (etanercept) has also been associated with the manifestation of MS-like
demyelinating lesions due to the blockade of both sTNF and mTNF, confirming the idea
that mTNF probably has a dominant role in the regenerative process and resolution of
inflammation [33]. It has been recently suggested that the protective function in inflamed
central nervous system pathology by T regulatory cells requires the surface expression of
TNF-R2, therefore explaining the potential of some adverse effects of anti-TNF therapy in
patients [34].
In addition, one of the possible explanations of the anti-TNF ineffectiveness could
be the limited access to the CNS, which would not allow the achievement of an adequate
therapeutic level of the drugs [2]. In active MS, the permeability of the blood-brain barrier
(BBB) is only mildly modified, so TNF antagonists are enabled to penetrate in CNS.
Several experimental studies in mice deficient for TNF-R1 have demonstrated that
it has a detrimental role as mice were entirely protected against EAE disease, whereas
TNF-R2-KO mice exhibited exacerbated disease, enhanced Th1 cytokine production and
enhanced CD4+ T cell infiltration in the CNS, suggesting an immunomodulatory and
protective role for TNF-R2 signalling [35–37].
Many aspects of the role and function of the TNF in MS still need to be explored: the
different role and balance between sTNF and mTNF (pro-inflammatory role vs. homeostatic
functions), rather than the TNF-R1/TNF-R2 ratio. We need to understand if the soluble
molecules (sTNF and sTNF-R1/2) are in equilibrium with the corresponding membrane
bound proteins (mTNF and TNF-R1/2) and whether the increase of TNF in the CSF in
MS is dependent on B clonal expansion or not. The topic is really complex and needs to
be adequately investigated with new in vitro and animal model studies. One therapeutic
solution could be to intervene at the level of downstream signalling rather than the ligand-
receptor interaction in order to increase the specificity against the pathogenetic process.
5. Conclusions
Our study confirms that TNF is significantly elevated in the CSF of MS patients at the
time of diagnosis and that soluble TNF-R1 predominates over TNF-R2 even in physiological
conditions (5:1 ratio) with a greater overexpression of TNF-R1 in patients compared to
controls. Since there is not a single unequivocal marker of inflammation and demyelination
at early stages of MS, we think that the determination of TNF and its receptor balance
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in the CSF could contribute, together with advanced MRI data, to identify patients with
a worse prognosis who need more aggressive treatment immediately. In addition, this
study suggests that there is an imbalance between TNFR1 and TNFR2 signalling in patients
with MS from the earliest clinical events and that this can have an important prognostic
meaning, announcing the appearance of new cortical lesions and a clinical worsening of the
disease. The differential roles of TNF in MS are mediated by multiple pathways, therefore
addressing a possible shift of the balance between TNF-R1 and TNF-R2 signalling in the
pathological condition could be an important avenue for MS treatment, but further studies
are necessary.
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Pathway associated with CSF molecular profile of MS-High patients compared to MS-Low patients;
Table S4: IPA Disease and Functions categories related to CSF profile of MS-High patients compared
to MS-Low patients; Table S5: Functional annotations encompassed Inflammatory Response category
of MS-High patients’ CSF profile; Table S6: Functional annotations encompassed Lymphoid Tissue
Structure and Development category of MS-High patients’ CSF profile.
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